High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study - PubMed (original) (raw)
Clinical Trial
. 2008 Jun 1;111(11):5371-9.
doi: 10.1182/blood-2007-11-124958. Epub 2008 Mar 31.
Michael D Radmacher, Amy S Ruppert, Susan P Whitman, Peter Paschka, Krzysztof Mrózek, Claudia D Baldus, Tamara Vukosavljevic, Chang-Gong Liu, Mary E Ross, Bayard L Powell, Albert de la Chapelle, Jonathan E Kolitz, Richard A Larson, Guido Marcucci, Clara D Bloomfield; Cancer and Leukemia Group B (CALGB)
Collaborators, Affiliations
- PMID: 18378853
- PMCID: PMC2396728
- DOI: 10.1182/blood-2007-11-124958
Clinical Trial
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
Christian Langer et al. Blood. 2008.
Abstract
BAALC expression is considered an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML), but has yet to be investigated together with multiple other established prognostic molecular markers in CN-AML. We analyzed BAALC expression in 172 primary CN-AML patients younger than 60 years of age, treated similarly on CALGB protocols. High BAALC expression was associated with FLT3-ITD (P = .04), wild-type NPM1 (P < .001), mutated CEBPA (P = .003), MLL-PTD (P = .009), absent FLT3-TKD (P = .005), and high ERG expression (P = .05). In multivariable analysis, high BAALC expression independently predicted lower complete remission rates (P = .04) when adjusting for ERG expression and age, and shorter survival (P = .04) when adjusting for FLT3-ITD, NPM1, CEBPA, and white blood cell count. A gene-expression signature of 312 probe sets differentiating high from low BAALC expressers was identified. High BAALC expression was associated with overexpression of genes involved in drug resistance (MDR1) and stem cell markers (CD133, CD34, KIT). Global microRNA-expression analysis did not reveal significant differences between BAALC expression groups. However, an analysis of microRNAs that putatively target BAALC revealed a potentially interesting inverse association between expression of miR-148a and BAALC. We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile.
Figures
Figure 1
Outcome of cytogenetically normal AML patients according to BAALC expression levels. (A) Disease-free survival. (B) Overall survival.
Figure 2
Heat map of the BAALC signature. Columns represent samples and rows represent genes ordered by hierarchical cluster analysis using average linkage and one minus Pearson correlation as the distance metric. Shading indicates relative expression of each gene with respect to the gene's median expression (black equal to, red above, and blue below the median value).
References
- Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336. - PubMed
- Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320. - PubMed
- Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood. Rev. 2004;18:115–136. - PubMed
- Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res. 2001;61:7233–7239. - PubMed
- Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372–4380. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA098933/CA/NCI NIH HHS/United States
- CA016058/CA/NCI NIH HHS/United States
- CA089341/CA/NCI NIH HHS/United States
- R01 CA089341/CA/NCI NIH HHS/United States
- CA077658/CA/NCI NIH HHS/United States
- U24 CA114725/CA/NCI NIH HHS/United States
- U10 CA101140/CA/NCI NIH HHS/United States
- R01 CA098933/CA/NCI NIH HHS/United States
- K01 CA096887/CA/NCI NIH HHS/United States
- P30 CA016058/CA/NCI NIH HHS/United States
- CA114725/CA/NCI NIH HHS/United States
- CA096887/CA/NCI NIH HHS/United States
- CA101140/CA/NCI NIH HHS/United States
- U10 CA077658/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous